{"id":732386,"date":"2023-02-16T16:43:07","date_gmt":"2023-02-16T21:43:07","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/vir-biotechnology-to-provide-corporate-update-and-report-fourth-quarter-and-full-year-2022-financial-results-on-february-23-2023\/"},"modified":"2023-02-16T16:43:07","modified_gmt":"2023-02-16T21:43:07","slug":"vir-biotechnology-to-provide-corporate-update-and-report-fourth-quarter-and-full-year-2022-financial-results-on-february-23-2023","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/vir-biotechnology-to-provide-corporate-update-and-report-fourth-quarter-and-full-year-2022-financial-results-on-february-23-2023\/","title":{"rendered":"Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and\u00a0Full Year 2022 Financial Results on February 23, 2023"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">SAN FRANCISCO, Feb.  16, 2023  (GLOBE NEWSWIRE) &#8212; Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the fourth quarter and full year ended December 31, 2022, on Thursday, February 23, 2023.<\/p>\n<p align=\"justify\">The corporate update and financial results will be provided via a press release after market close and will be accessible under Press Releases in the Investors section of the Vir website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=SE1lLo5Mn6F9qrrY7Ff5c6kDj2uO0n4DWwnMGojiXF6vWk7rwpbVxDlHDrslwKbZXd4m1OZeLYoSetjqAB9sSg==\" rel=\"nofollow noopener\" target=\"_blank\">www.vir.bio<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About Vir Biotechnology<\/strong><br \/>\n        <br \/>Vir Biotechnology\u00a0is a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting COVID-19, hepatitis B and D viruses, influenza A and human immunodeficiency virus. Vir routinely posts information that may be important to investors on its website.<\/p>\n<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc1MTI4MCM1NDEwNDMyIzIxODgzMzc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/OTEzODNmNzAtNTVlZi00ODYxLWI3ZGItZWVhZTEyYmI4Njg1LTExOTk4OTA=\/tiny\/Vir-Biotechnology-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\">\n<pre>Contacts:\r\n\r\nCarly Scaduto\r\nSenior Director, Media Relations\r\ncscaduto@vir.bio\r\n+1 314-368-5189<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN FRANCISCO, Feb. 16, 2023 (GLOBE NEWSWIRE) &#8212; Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the fourth quarter and full year ended December 31, 2022, on Thursday, February 23, 2023. The corporate update and financial results will be provided via a press release after market close and will be accessible under Press Releases in the Investors section of the Vir website at www.vir.bio. About Vir Biotechnology Vir Biotechnology\u00a0is a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vir-biotechnology-to-provide-corporate-update-and-report-fourth-quarter-and-full-year-2022-financial-results-on-february-23-2023\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and\u00a0Full Year 2022 Financial Results on February 23, 2023&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-732386","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and\u00a0Full Year 2022 Financial Results on February 23, 2023 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vir-biotechnology-to-provide-corporate-update-and-report-fourth-quarter-and-full-year-2022-financial-results-on-february-23-2023\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and\u00a0Full Year 2022 Financial Results on February 23, 2023 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN FRANCISCO, Feb. 16, 2023 (GLOBE NEWSWIRE) &#8212; Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the fourth quarter and full year ended December 31, 2022, on Thursday, February 23, 2023. The corporate update and financial results will be provided via a press release after market close and will be accessible under Press Releases in the Investors section of the Vir website at www.vir.bio. About Vir Biotechnology Vir Biotechnology\u00a0is a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of &hellip; Continue reading &quot;Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and\u00a0Full Year 2022 Financial Results on February 23, 2023&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/vir-biotechnology-to-provide-corporate-update-and-report-fourth-quarter-and-full-year-2022-financial-results-on-february-23-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-16T21:43:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc1MTI4MCM1NDEwNDMyIzIxODgzMzc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vir-biotechnology-to-provide-corporate-update-and-report-fourth-quarter-and-full-year-2022-financial-results-on-february-23-2023\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vir-biotechnology-to-provide-corporate-update-and-report-fourth-quarter-and-full-year-2022-financial-results-on-february-23-2023\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and\u00a0Full Year 2022 Financial Results on February 23, 2023\",\"datePublished\":\"2023-02-16T21:43:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vir-biotechnology-to-provide-corporate-update-and-report-fourth-quarter-and-full-year-2022-financial-results-on-february-23-2023\\\/\"},\"wordCount\":171,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vir-biotechnology-to-provide-corporate-update-and-report-fourth-quarter-and-full-year-2022-financial-results-on-february-23-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc1MTI4MCM1NDEwNDMyIzIxODgzMzc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vir-biotechnology-to-provide-corporate-update-and-report-fourth-quarter-and-full-year-2022-financial-results-on-february-23-2023\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vir-biotechnology-to-provide-corporate-update-and-report-fourth-quarter-and-full-year-2022-financial-results-on-february-23-2023\\\/\",\"name\":\"Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and\u00a0Full Year 2022 Financial Results on February 23, 2023 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vir-biotechnology-to-provide-corporate-update-and-report-fourth-quarter-and-full-year-2022-financial-results-on-february-23-2023\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vir-biotechnology-to-provide-corporate-update-and-report-fourth-quarter-and-full-year-2022-financial-results-on-february-23-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc1MTI4MCM1NDEwNDMyIzIxODgzMzc=\",\"datePublished\":\"2023-02-16T21:43:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vir-biotechnology-to-provide-corporate-update-and-report-fourth-quarter-and-full-year-2022-financial-results-on-february-23-2023\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vir-biotechnology-to-provide-corporate-update-and-report-fourth-quarter-and-full-year-2022-financial-results-on-february-23-2023\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vir-biotechnology-to-provide-corporate-update-and-report-fourth-quarter-and-full-year-2022-financial-results-on-february-23-2023\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc1MTI4MCM1NDEwNDMyIzIxODgzMzc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc1MTI4MCM1NDEwNDMyIzIxODgzMzc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vir-biotechnology-to-provide-corporate-update-and-report-fourth-quarter-and-full-year-2022-financial-results-on-february-23-2023\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and\u00a0Full Year 2022 Financial Results on February 23, 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and\u00a0Full Year 2022 Financial Results on February 23, 2023 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/vir-biotechnology-to-provide-corporate-update-and-report-fourth-quarter-and-full-year-2022-financial-results-on-february-23-2023\/","og_locale":"en_US","og_type":"article","og_title":"Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and\u00a0Full Year 2022 Financial Results on February 23, 2023 - Market Newsdesk","og_description":"SAN FRANCISCO, Feb. 16, 2023 (GLOBE NEWSWIRE) &#8212; Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the fourth quarter and full year ended December 31, 2022, on Thursday, February 23, 2023. The corporate update and financial results will be provided via a press release after market close and will be accessible under Press Releases in the Investors section of the Vir website at www.vir.bio. About Vir Biotechnology Vir Biotechnology\u00a0is a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of &hellip; Continue reading \"Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and\u00a0Full Year 2022 Financial Results on February 23, 2023\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/vir-biotechnology-to-provide-corporate-update-and-report-fourth-quarter-and-full-year-2022-financial-results-on-february-23-2023\/","og_site_name":"Market Newsdesk","article_published_time":"2023-02-16T21:43:07+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc1MTI4MCM1NDEwNDMyIzIxODgzMzc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vir-biotechnology-to-provide-corporate-update-and-report-fourth-quarter-and-full-year-2022-financial-results-on-february-23-2023\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vir-biotechnology-to-provide-corporate-update-and-report-fourth-quarter-and-full-year-2022-financial-results-on-february-23-2023\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and\u00a0Full Year 2022 Financial Results on February 23, 2023","datePublished":"2023-02-16T21:43:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vir-biotechnology-to-provide-corporate-update-and-report-fourth-quarter-and-full-year-2022-financial-results-on-february-23-2023\/"},"wordCount":171,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vir-biotechnology-to-provide-corporate-update-and-report-fourth-quarter-and-full-year-2022-financial-results-on-february-23-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc1MTI4MCM1NDEwNDMyIzIxODgzMzc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vir-biotechnology-to-provide-corporate-update-and-report-fourth-quarter-and-full-year-2022-financial-results-on-february-23-2023\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/vir-biotechnology-to-provide-corporate-update-and-report-fourth-quarter-and-full-year-2022-financial-results-on-february-23-2023\/","name":"Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and\u00a0Full Year 2022 Financial Results on February 23, 2023 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vir-biotechnology-to-provide-corporate-update-and-report-fourth-quarter-and-full-year-2022-financial-results-on-february-23-2023\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vir-biotechnology-to-provide-corporate-update-and-report-fourth-quarter-and-full-year-2022-financial-results-on-february-23-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc1MTI4MCM1NDEwNDMyIzIxODgzMzc=","datePublished":"2023-02-16T21:43:07+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vir-biotechnology-to-provide-corporate-update-and-report-fourth-quarter-and-full-year-2022-financial-results-on-february-23-2023\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/vir-biotechnology-to-provide-corporate-update-and-report-fourth-quarter-and-full-year-2022-financial-results-on-february-23-2023\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vir-biotechnology-to-provide-corporate-update-and-report-fourth-quarter-and-full-year-2022-financial-results-on-february-23-2023\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc1MTI4MCM1NDEwNDMyIzIxODgzMzc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc1MTI4MCM1NDEwNDMyIzIxODgzMzc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vir-biotechnology-to-provide-corporate-update-and-report-fourth-quarter-and-full-year-2022-financial-results-on-february-23-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and\u00a0Full Year 2022 Financial Results on February 23, 2023"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/732386","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=732386"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/732386\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=732386"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=732386"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=732386"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}